The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.
Frederike Bensch
No relevant relationships to disclose
Laetitia E. Lamberts
No relevant relationships to disclose
Marjolijn N. Lub-de Hooge
No relevant relationships to disclose
Anton G.T. Terwisscha van Scheltinga
No relevant relationships to disclose
Johan R. de Jong
No relevant relationships to disclose
Jourik A. Gietema
Research Funding - AbbVie; Roche; Siemens
Carolien P. Schroder
No relevant relationships to disclose
Michiel M. Smeenk
No relevant relationships to disclose
Wolfgang Jacob
Employment or Leadership Position - Roche
Keelara Abiraj
Employment or Leadership Position - Roche
Michaela Wolf
Employment or Leadership Position - Roche
Stock Ownership - Roche
Celine Adessi
Employment or Leadership Position - Roche
Georgina Meneses-Lorente
Employment or Leadership Position - Roche
Stock Ownership - Roche
Magdalena Zajac
Employment or Leadership Position - Roche
Martin Weisser
Employment or Leadership Position - Roche
Stock Ownership - Roche
Adrienne H. Brouwers
No relevant relationships to disclose
Elisabeth De Vries
No relevant relationships to disclose